Key Takeaways
- The U.S. government has granted Moderna nearly $600 million to expedite bird flu vaccine development, specifically targeting avian strains with pandemic potential.
- Moderna is preparing for phase 3 trials of its mRNA-1018 vaccine, which has shown promising results against H5 and H7 avian influenza viruses.
- The funding aims to support the creation of additional flu vaccines and enhance preparedness against future influenza pandemics.
Vaccine Development Acceleration
The U.S. government has invested approximately $600 million in Moderna to expedite the development of bird flu vaccines and mRNA vaccines for other influenza strains that pose a pandemic risk. This funding is part of a collaboration with the Department of Health and Human Services (HHS), through its Biomedical Advanced Research and Development Authority (BARDA), which has been ongoing since 2023.
Moderna previously received $176 million from BARDA for similar initiatives. The latest funding, announced on January 17, aims to accelerate the development of a vaccine tailored to the H5N1 avian influenza strain and to enhance the data supporting the use of mRNA vaccine technology for potential pandemic scenarios.
The company is set to launch a phase 3 clinical trial for mRNA-1018, a promising vaccine that targets H5 and H7 avian influenza viruses. Initial results from phase 1/2 studies have been positive, and the findings are anticipated to be disclosed at a forthcoming medical conference. Additionally, Moderna plans to conduct a phase 3 trial for a vaccine against the H7N9 strain.
The HHS anticipates that Moderna will design up to four new flu vaccines, progressing into phase 1 studies. The intent is to collect essential data to facilitate the rapid development of vaccines aimed at addressing various influenza virus subtypes capable of causing pandemics.
This initiative is part of BARDA’s Rapid Response Partnership Vehicle Consortium, which was established during the final days of the Biden administration. This funding arrives at a crucial time for Moderna, which recently announced a reduction in its financial guidance and the need for $1 billion in cost-cutting measures due to disappointing sales of COVID-19 and respiratory syncytial virus vaccines.
Xavier Becerra, the outgoing HHS Secretary, emphasized the unpredictability and potential danger of avian flu variants, asserting that the acceleration of vaccine development is a top priority for the administration. The goal is to ensure that citizens are equipped with the necessary tools to safeguard their health against future influenza outbreaks.
To date, the Centers for Disease Control and Prevention (CDC) has confirmed 67 human cases of avian influenza in the U.S., with one fatality recorded. While the CDC currently assesses the public health risk as “low,” it continues to monitor the situation closely, collaborating with states to oversee individuals with animal exposures. This proactive stance reflects an ongoing commitment to public health preparedness amidst evolving infectious disease threats.
The content above is a summary. For more details, see the source article.